Zantac Recalled In All Markets
GlaxoSmithKline said on October 8, 2019 that it was recalling their popular heartburn medication Zantac in all markets as a precaution. This comes mere days after the U.S. Food and Drug Administration (FDA) found “unacceptable” levels of the carcinogen NDMA in the medicine.
Ranitidine, the active ingredient in Zantac, is merely the latest drug in which carcinogenic impurities have been found. Valsartan and other blood pressure and heart failure medicines have also been recently recalled due to being contaminated with carcinogens.
The recall applies to a Zantac syrup, a Zantac injection and tablets of 150 and 300 milligram dosages, according to Britain’s Medicines and Healthcare products Regulatory Agency (MHRA). MHRA says the recall does not apply to over-the-counter 75 mg dosage Zantac products, which are produced by a different company.
Drug May Break Down Into Carcinogen In Human Body
A September 2019 FDA safety alert said that some ranitidine medicines, including Zantac, contain a carcinogenic “impurity” known as NDMA. However, David Light, CEO of lab testing company Valisure, suspects the problem with ranitidine goes beyond a mere impurity and also has to do with what happens to ranitidine inside the human body.
“Ranitidine, the active ingredient in Zantac, appears to us to be a fundamentally unstable molecule,” Light said. “In a variety of conditions — conditions of the lab, conditions of the human body — it can break down and then form the carcinogen, NDMA.”
Valisure says they are now investigating what happens to ranitidine inside the human body once it is exposed to stomach acid.
The possibility that ranitidine can break down into NDMA inside the body was suggested in 2016 in research published by Stanford University’s William Mitch and Syracuse University’s Teng Zeng. Their study saw urine tests of volunteers who were given a tablet of Zantac showing NDMA levels over 400 times greater than what the FDA considers acceptable.
The U.S. Environmental Protection Agency (EPA) has classified NDMA as a probable human carcinogen, and in high doses it is very toxic to the liver and can cause fibrosis of the liver in rats. It is also known to induce liver tumors in rats via chronic exposure to low doses. In fact, rats are literally intentionally given NDMA to give them cancer for the purpose of cancer research. NDMA has also seen media exposure for its use in poisoning incidents.
What Are NDMA Side Effects?
- Liver Cancer
- Colorectal Cancer
- Stomach/Gastric Cancer
- Kidney Cancer
- Bladder Cancer
- Pancreatic Cancer
- Liver Failure, requiring hospitalization
How To Join The Zantac Lawsuit
The attorneys of Nadrich & Cohen are actively investigating and pursuing claims on behalf of Zantac and Ranitidine users who have been diagnosed with one of the above cancer types or liver failure following use of the drug. If you believe that you or a loved one may have a claim, contact us now at 1-800-718-4658. We are pursuing Zantac Lawsuit claims nationwide.